Skip to main content
All lobbying filings

HIV AND HEPATITIS POLICY INSTITUTE

Lobbying for HIV AND HEPATITIS POLICY INSTITUTE · Patient advocacy

 Filing Registration
3rd Quarter (July 1 - Sep 30) 2025 · District of Columbia · posted Sep 29, 2025

Official filing document

 Lobbying activity 5
Budget/Appropriations

Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.

Health Issues

Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.

Insurance

Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.

Medicare/Medicaid

Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.

Pharmacy

Budget and appropriations for domestic HIV and hepatitis prevention through the CDC and HIV treatment through HRSA; authorizing legislation and Executive Branch programs to support access to HIV prevention medication, treatment, and testing services and viral hepatitis treatment and testing services; and legislation and Executive Branch programs impacting patient access to affordable healthcare and prescription drugs offered through Medicaid, Medicare, and the private insurance market.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.

Report a problem